Luteinizing-hormone releasing hormone (LHRH) analogue, which is widely used for prostate cancer treatment, induces a large increase in LH and follicle-stimulating hormone (FSH) levels, like after menopause in women, during the first few days after initial administration (8), and it is unknown that old male patients who undergo LHRH analogue treatment have detectable serum HCG like postmenopausal women. The gene discussed is BRD2; the disease is prostate carcinoma.